Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olanzapine-induced lipid metabolism disorder mechanism cohort study
ChiCTR2300069325Phase 4Not yet recruiting
- Sponsor
- Nanchong City Central Hospital
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of olanzapine in Schizophrenia Spectrum and Other Psychotic Disorders (SZ) (2 arms), sponsored by Nanchong City Central Hospital. Primary endpoint: triglyceride. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
olanzapine
03
Conditions
Schizophrenia Spectrum and Other Psychotic Disorders (SZ)
Beyond the preview
Go deeper on ChiCTR2300069325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300069325.